Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Infection ; 52(3): 955-983, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38133713

RESUMO

PURPOSE: The aim of this study was to elucidate the factors associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may initiate cytokine cascades and correlate the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) with their serum cytokine profiles. METHODS: Recombinant baculoviruses displaying SARS-CoV-2 spike or nucleocapsid protein were constructed and transfected into A549 cells and THP-1-derived macrophages, to determine which protein initiate cytokine release. SARS-CoV-2-specific antibody titers and cytokine profiles of patients with COVID-19 were determined, and the results were associated with their clinical characteristics, such as development of pneumonia or length of hospital stay. RESULTS: The SARS-CoV-2 nucleocapsid protein, rather than the spike protein, triggers lung epithelial A549 cells to express IP-10, RANTES, IL-16, MIP-1α, basic FGF, eotaxin, IL-15, PDGF-BB, TRAIL, VEGF-A, and IL-5. Additionally, serum CTACK, basic FGF, GRO-α, IL-1α, IL-1RA, IL-2Rα, IL-9, IL-15, IL-16, IL-18, IP-10, M-CSF, MIF, MIG, RANTES, SCGF-ß, SDF-1α, TNF-α, TNF-ß, VEGF, PDGF-BB, TRAIL, ß-NGF, eotaxin, GM-CSF, IFN-α2, INF-γ, and MCP-1 levels were considerably increased in patients with COVID-19. Among them, patients with pneumonia had higher serum IP-10 and M-CSF levels than patients without. Patients requiring less than 3 weeks to show negative COVID-19 tests after contracting COVID-19 had higher serum IP-10 levels than the remaining patients. CONCLUSION: Our study revealed that nucleocapsid protein, lung epithelial cells, and IP-10 may be potential targets for the development of new strategies to prevent, or control, severe COVID-19.


Assuntos
COVID-19 , Proteínas do Nucleocapsídeo de Coronavírus , Citocinas , Células Epiteliais , SARS-CoV-2 , Glicoproteína da Espícula de Coronavírus , Humanos , COVID-19/imunologia , COVID-19/sangue , Glicoproteína da Espícula de Coronavírus/imunologia , SARS-CoV-2/imunologia , Citocinas/sangue , Feminino , Masculino , Pessoa de Meia-Idade , Células Epiteliais/virologia , Células Epiteliais/imunologia , Proteínas do Nucleocapsídeo de Coronavírus/imunologia , Idoso , Células A549 , Pulmão/patologia , Pulmão/imunologia , Síndrome da Liberação de Citocina/imunologia , Síndrome da Liberação de Citocina/sangue , Adulto , Anticorpos Antivirais/sangue , Fosfoproteínas
2.
J Chin Med Assoc ; 85(9): 922-927, 2022 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-35727096

RESUMO

BACKGROUND: Coronavirus disease 2019 (COVID-19) inpatients may acquire infections from other pathogens during hospital admission. This is the first research on this subject to be reported from Taiwan. METHODS: Confirmed COVID-19 inpatients were enrolled in this study from January 1, 2020 to July 31, 2021. Various types of pathogens in COVID-19 inpatients, with hospital-acquired infections, were identified and analyzed. The clinical characteristics of COVID-19 patients with and without hospital-acquired infections were reviewed and compared. RESULTS: Of the 204 patients included in the study, 32 (15.7%) patients experienced at least one infectious episode. Of 113 recorded episodes of infection, the predominant type was bacterial (88 of 113 infections, 77.9%); the most frequently isolated bacteria were Acinetobacter spp., followed by Stenotrophomonas maltophilia . With regard to viral infections (19 of 113, 16.8%), the Epstein-Barr virus ranked first place among the identified viruses. Four (3.5%) and 2 (1.8%) of 113 infectious episodes were caused by fungi and atypical pathogens. A multivariate analysis revealed that steroid use was an independent factor in hospital-acquired infections (odds ratio [OR], 6.97; 95% confidence interval [CI], 1.15-42.43; p = 0.035). Patients with hospital-acquired infections were associated with increased 28-day and in-hospital mortality (18.8% vs 5.8% and 31.3% and 5.8%; p = 0.023 and <0.01, respectively), and a longer hospital stay (34 vs 19 days; p < 0.001), compared to those without hospital-acquired infections. CONCLUSION: Our study revealed the unique local epidemiology of hospital-acquired infections among COVID-19 inpatients in Taiwan. These patients were associated with increased mortality and prolonged hospital admissions.


Assuntos
COVID-19 , Infecção Hospitalar , Infecções por Vírus Epstein-Barr , Infecção Hospitalar/epidemiologia , Herpesvirus Humano 4 , Hospitais , Humanos , Estudos Retrospectivos , Esteroides , Taiwan/epidemiologia
3.
PLoS One ; 13(9): e0204568, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30265690

RESUMO

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a race-specific malignancy. The nasal cavity is the main entry point for air pollutants or poisonous gases into the human body. However, the risk of NPC in populations exposed to air pollution remains unknown. METHODS: We combined data from the Taiwan Air Quality Monitoring Database (TAQMD) and the Longitudinal Health Insurance Database (LHID) to assess the risk of NPC in a population exposed to air pollution. RESULTS: Multivariate analysis revealed positive trends for the association between the risk of NPC and exposure to air pollution. After adjusting for potential covariates, the risk of developing NPC increased with the increase in nitrogen dioxide (NO2) and fine particulate matter (PM2.5) exposure concentrations from 1.39 to 2.28 and 2.01 to 1.97, respectively, compared to the risks at the lowest concentration levels. CONCLUSIONS: We identified a significant risk of NPC in a population exposed to air pollution. However, this study had several limitations. Moreover, additional experimental and clinical studies on the associations between environmental factors and NPC risk are warranted.


Assuntos
Poluição do Ar/efeitos adversos , Carcinoma Nasofaríngeo/etiologia , Adulto , Idoso , Poluentes Atmosféricos/efeitos adversos , Poluentes Atmosféricos/análise , Poluição do Ar/análise , Bases de Dados Factuais , Exposição Ambiental/efeitos adversos , Exposição Ambiental/análise , Monitoramento Ambiental , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Carcinoma Nasofaríngeo/epidemiologia , Dióxido de Nitrogênio/efeitos adversos , Dióxido de Nitrogênio/análise , Material Particulado/efeitos adversos , Material Particulado/análise , Fatores de Risco , Dióxido de Enxofre/efeitos adversos , Dióxido de Enxofre/análise , Taiwan/epidemiologia , Adulto Jovem
4.
J Antimicrob Chemother ; 71(12): 3441-3448, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27543656

RESUMO

OBJECTIVES: According to our previous study, OXA-58 translocates to the periplasm via the Sec pathway in carbapenem-resistant Acinetobacter baumannii (CRAb). In the present study, carbapenem-hydrolysing class D ß-lactamases (CHDLs) belonging to the OXA-23, OXA-40 and OXA-51 families were examined to determine whether they are also Sec-dependent. Additionally, the effects of SecA inhibitors combined with carbapenems against CHDL-producing CRAb were examined. METHODS: Cell fractionation and western blot analyses were performed to detect periplasmic His-tagged CHDLs. A chequerboard analysis with pairwise combinations of carbapenems (imipenem or meropenem) and SecA inhibitors (rose bengal, sodium azide or erythrosin B) was performed using six clinical CRAb isolates harbouring different CHDL genes. The fractional inhibitory concentration (FIC) index was determined. The combination with the lowest FIC index was subjected to a time-kill analysis to examine synergistic effects. RESULTS: In an in silico analysis, the CHDLs OXA-23, OXA-40 and OXA-51 were preferentially translocated via the Sec system. The SecA inhibitor rose bengal decreased periplasmic translocation of His-tagged OXA-23 and OXA-83 (belonging to the OXA-51 family), but not OXA-72 (belonging to the OXA-40 family) from ATCC 15151 transformants. Imipenem or meropenem with rose bengal showed synergistic effects (FIC index, ≤0.5) for six and four clinical isolates, respectively. Imipenem or meropenem with sodium azide showed no interactions (FIC index, 0.5-4) against all clinical isolates. Imipenem and rose bengal had the lowest FIC index and showed synergy at 24 h in the time-kill assay. CONCLUSIONS: Combinations of SecA inhibitors and carbapenems have synergistic effects against CHDL-producing CRAb.


Assuntos
Acinetobacter baumannii/efeitos dos fármacos , Adenosina Trifosfatases/antagonistas & inibidores , Antibacterianos/farmacologia , Proteínas de Bactérias/antagonistas & inibidores , Carbapenêmicos/farmacologia , Sinergismo Farmacológico , Inibidores Enzimáticos/farmacologia , Canais de Translocação SEC/antagonistas & inibidores , beta-Lactamases/metabolismo , Humanos , Testes de Sensibilidade Microbiana , Transporte Proteico/efeitos dos fármacos , Proteínas SecA
5.
BMC Infect Dis ; 15: 400, 2015 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-26423424

RESUMO

BACKGROUND: Acinetobacter ursingii bacteremia is rarely reported. We investigated the incidence and clinical features of A. ursingii bacteremia, performance of the identification system, and antimicrobial susceptibility of the isolates. Acinetobacter ursingii bacteremia patients were compared with A. baumannii bacteremia patients. METHODS: In this 9-year retrospective study, A. ursingii was identified using 16S rRNA and 16S-23S rRNA internal transcribed spacer sequence analysis. The performances of the Vitek 2, Phoenix, and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometer systems for identifying isolates were tested. Pulsed-field gel electrophoresis (PFGE) was used to determine the clonality of the isolates. The minimal inhibitory concentrations of the antimicrobials were determined using the Vitek 2 system. RESULTS: Nineteen patients were identified. Acinetobacter ursingii was noted in 1.5-5.2 % of all Acinetobacter bacteremia cases. For the PFGE analysis, two isolates had smeared DNA, two had 93 % similarity, and 15 had similarity <80 %. Among 16 patients with complete medical records, 10 (62.5 %) had no identifiable source of A. ursingii bacteremia. Most patients (n = 12) had underlying malignant disease. Patients with A. ursingii bacteremia had lower Acute Physiology and Chronic Health Evaluation II scores than those with A. baumannii bacteremia (median [interquartile range], 17.1 [10.0-24.7] vs. 24.9 [14.6-35.1]). Patients with A. ursingii bacteremia were also less likely admitted to the intensive care unit than patients with A. baumannii bacteremia (18.8 % vs 63.5 %, p value < 0.01). About half of the patients with A. ursingii (50.8 %) and A. baumannii bacteremia (62.5 %) had received inappropriate antimicrobial therapy within 48 h after bacteremia onset. However, patients with A. ursingii bacteremia had significantly lower 14-day (6.25 % vs 29.8 %, p value = 0.04) and 28-day mortality rates (6.25 % vs 37.3 %, p value = 0.02) than patients with A. baumannii bacteremia. Nine isolates (47.4 %) were correctly identified as A. ursingii and the other 10 isolates (52.6 %) were incorrectly identified as A. lwoffii by the Vitek 2 system. The Phoenix system incorrectly identified all 19 isolates. The MALDI-TOF mass spectrometer system correctly identified all 19 isolates. All the A. ursingii isolates were resistant or showed intermediate susceptibility to ceftriaxone and ceftazidime, but were susceptible to levofloxacin and imipenem. CONCLUSIONS: Acinetobacter ursingii is a rare pathogen that mostly caused primary bacteremia in patients with malignancies. Patients with A. ursingii bacteremia had significantly lower disease severity and mortality rates than patients with A. baumannii bacteremia.


Assuntos
Infecções por Acinetobacter/epidemiologia , Acinetobacter/genética , Bacteriemia/epidemiologia , Acinetobacter/efeitos dos fármacos , Acinetobacter/isolamento & purificação , Infecções por Acinetobacter/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/farmacologia , Anti-Infecciosos/uso terapêutico , Bacteriemia/tratamento farmacológico , Ceftazidima/farmacologia , Ceftriaxona/farmacologia , Eletroforese em Gel de Campo Pulsado , Feminino , Genótipo , Humanos , Imipenem/farmacologia , Incidência , Levofloxacino/farmacologia , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Fenótipo , RNA Ribossômico 16S/genética , Estudos Retrospectivos
6.
J Hazard Mater ; 291: 1-8, 2015 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-25748996

RESUMO

This research investigated the effects of manganese oxide (MnOx) impregnation on the physical/chemical properties and multi pollutant control effectiveness of Hg(0) and NO using a V2O5-WO3/TiO2-SiO2 selective catalytic reduction (SCR) catalyst. Raw and MnOx-treated SCR samples were bean-shaped nanoparticles with sizes within 10-30 nm. Impregnating MnOx of ≤ 5 wt% caused limited changes in physical properties of the catalyst. The decrease in surface area when the impregnated MnOx amount was 10 wt% may stem from the pore blockage and particle growth or aggregation of the catalyst. Mn(4+) was the main valence state of impregnated MnOx. Apparent crystallinity of MnOx was not observed based on X-ray diffraction. MnOx impregnation enhanced the Hg(0) oxidation and NO/SO2 removal of SCR catalyst. The 5 and 10% MnOx-impregnated samples had the greatest multi pollutant control potentials for Hg(0) oxidation and NO removal; however, the increasing SO2 removal that may be mainly due to SO2-SO3 conversion should be cautioned. HCl and O2 greatly promoted Hg(0) oxidation. SO2 enhanced Hg(0) oxidation at ≤ 200 ppm while NO and NH3 consistently inhibited Hg(0) oxidation. Elevating flue gas temperature enhanced Hg(0) oxidation. Overall, MnOx-impregnated catalysts show stable and consistent multi pollutant removal effectiveness under the test conditions.


Assuntos
Poluentes Ocupacionais do Ar/análise , Gases/análise , Compostos de Manganês/química , Compostos de Mercúrio/análise , Óxido Nitroso/análise , Óxidos/química , Catálise , Nitrogênio/análise , Dióxido de Silício/química , Temperatura , Titânio/química , Tungstênio/química , Compostos de Vanádio/química , Difração de Raios X
7.
J Microbiol Immunol Infect ; 44(6): 442-8, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21602111

RESUMO

BACKGROUND: Cytomegalovirus (CMV) is a pathogen and can cause life-threatening infection in the patients with malignancies. This study was conducted to investigate the risk factors and outcomes of CMV viremia in patients with malignancies. METHODS: Data were collected with retrospective analysis from adults suffering from CMV viremia with underlying malignancies. A total of 107 patients were enrolled in a tertiary medical center in northern Taiwan from March 2008 to December 2009. RESULTS: Among the 107 patients who suffered with CMV viremia with an overall mortality rate of 56.1% (60/107), 75 patients (70.1%) had solid organ malignancies and 32 (29.9%) had hematological malignancies. Mechanical ventilation (p=0.048), leukocytosis (p=0.004), and lack of appropriate early treatment (p=0.011) were independent predisposing factors associated with higher mortality rate. CONCLUSIONS: CMV viremia predicts high mortality rate in cancer patients, especially in those with mechanical ventilation, leukocytosis, and lack of appropriate early treatment. Appropriate early antiviral therapy is recommended to improve outcomes.


Assuntos
Infecções por Citomegalovirus/patologia , Citomegalovirus/isolamento & purificação , Neoplasias/virologia , Viremia/patologia , Idoso , Idoso de 80 Anos ou mais , Antivirais/uso terapêutico , Distribuição de Qui-Quadrado , Infecções por Citomegalovirus/tratamento farmacológico , Infecções por Citomegalovirus/virologia , Feminino , Humanos , Leucocitose , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Respiração Artificial , Estudos Retrospectivos , Fatores de Risco , Taiwan , Viremia/tratamento farmacológico , Viremia/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA